Myriam Mendila describes how Novartis continued supporting cancer patients and healthcare professionals during the pandemic.

Spinal muscular atrophy (SMA) is the most common genetic casue of infant and toddler death. NIBR scientists are trying to make a back up gene take up the slack.

Novartis researchers are partnering with advocacy groups to understand the stigma and challenges facing patients with obesity.

An investigational treatment for an uncommon immunodeficiency disease races into clinical studies.

Researchers from Seattle Children’s and Novartis shed light on developmental brain disorders that lead to intractable epilepsy.

A certain leggy resident of the African grasslands is arousing a lot of interest among evolutionary biologists. They believe that study of giraffes' unique features could lead the way to advances in human health.

Novartis innovation and events such as mHealth Challenge enable patients to access data and personal information about their health via mobile devices.

A diminutive protein prompts a closer look at DNA dark matter.

Advanced Accelerator Applications is working on marrying targeted drug design with nuclear medicine technology to develop drugs that can recognize and treat diseases.